Amy Pfeiffer, M.B.A.

Ms. Pfeiffer leads business operations, finance and administration for Vivace. Prior to joining the company, she served in a number of accounting, administrative and operational roles for Afferent Pharmaceuticals, which was acquired by Merck. Prior to joining Afferent, Ms. Pfeiffer worked with Dr. Qiao and Dr. Post at LEAD Therapeutics, established and managed the business […]

Kelly Wong, Ph.D.

Kelly Wong is Vice President and Head of Program Management at Vivace Therapeutics and responsible for non-clinical development of VT3989. Previously, Kelly was a co-founder and Chief Operating Officer at Via Nova Therapeutics advancing 4 antiviral programs licensed from Novartis. He also served as the Head of Search and Evaluation at Jazz Pharmaceuticals focusing on […]

Ellen Lubman, M.B.A.

Ellen Lubman, M.B.A., currently serves as Chief Business and Strategy Officer of  Vivace Therapeutics. Prior to joining Vivace Therapeutics, Ms. Lubman served as Chief Business Officer and Head of Investor Relations at Werewolf Therapeutics, where she was a member of the Executive Committee and led strategic partnerships and corporate transactions totaling nearly $1.5 billion in […]